NCT06799520View on ClinicalTrials.gov

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG

VIS171

VIS171 will be administered as a SC injection.

Trial Locations (6)

1404

RECRUITING

Visterra Investigational Site, Sofia

8035

NOT_YET_RECRUITING

Visterra Investigational Site, Barcelona

11658

RECRUITING

Visterra Investigational Site, Bucharest

18014

NOT_YET_RECRUITING

Visterra Investigational Site, Granada

40006

RECRUITING

Visterra Investigational Site, Cluj-Napoca

MD-2025

RECRUITING

Visterra Investigational Site, Chisinau

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT06799520 - A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) | Biotech Hunter | Biotech Hunter